Armata Pharmaceuticals
Clinical-stage biotechnology company developing pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. Operates an integrated bench-to-clinic facility in Los Angeles with in-house discovery, synthetic biology/phage engineering, formulation development, cGMP clinical manufacturing and QA/QC, and conducts randomized controlled clinical trials targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus.
Industries
Nr. of Employees
medium (51-250)
Armata Pharmaceuticals
Marina Del Rey, California, United States
Patents
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
US-12268720-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
US-12239677-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
US-11654166-B2
View Details
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
US-12268720-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
US-12239677-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
US-11654166-B2
View DetailsProducts
AP-PA02
Phage cocktail program targeting Pseudomonas aeruginosa respiratory infections, developed for indications including cystic fibrosis and non-CF bronchiectasis; has completed Phase 1b/2 clinical evaluation.
AP-PA03
Phage program targeting Pseudomonas aeruginosa for pneumonia indications; listed in the pipeline as an unpartnered program in development.
AP-SA02
Intravenously administered bacteriophage product program targeting Staphylococcus aureus bacteremia and prosthetic joint infection; announced regulatory progression planning for Phase 3 initiation.
Synthetic Phage Platform
Armata's proprietary synthetic phage platform utilizes synthetic biology tools to engineer natural phages with improved pharmacological properties, expanded host range, improved potency, and biofilm disruption capabilities for treating multidrug-resistant bacterial infections.
AP-PA02
Phage cocktail program targeting Pseudomonas aeruginosa respiratory infections, developed for indications including cystic fibrosis and non-CF bronchiectasis; has completed Phase 1b/2 clinical evaluation.
AP-PA03
Phage program targeting Pseudomonas aeruginosa for pneumonia indications; listed in the pipeline as an unpartnered program in development.
AP-SA02
Intravenously administered bacteriophage product program targeting Staphylococcus aureus bacteremia and prosthetic joint infection; announced regulatory progression planning for Phase 3 initiation.
Synthetic Phage Platform
Armata's proprietary synthetic phage platform utilizes synthetic biology tools to engineer natural phages with improved pharmacological properties, expanded host range, improved potency, and biofilm disruption capabilities for treating multidrug-resistant bacterial infections.
Services
Assessment and case-by-case management of compassionate use requests for investigational bacteriophage products; triage and documentation workflow for treating physicians.
On-site production, testing, quality control and release of investigational clinical materials for phage therapeutic trials.
Assessment and case-by-case management of compassionate use requests for investigational bacteriophage products; triage and documentation workflow for treating physicians.
On-site production, testing, quality control and release of investigational clinical materials for phage therapeutic trials.
Expertise Areas
- Bacteriophage therapeutics development
- Synthetic biology and phage engineering
- Preclinical efficacy testing using animal infection models
- GMP clinical manufacturing and quality systems
Key Technologies
- Bacteriophage-based therapeutics
- Synthetic biology for phage modification
- cGMP clinical manufacturing
- Formulation for respiratory and intravenous delivery
News & Updates
Company-published article discussing renewed interest in bacteriophage therapy as an approach to antibiotic-resistant infections.
Company blog post discussing historical and modern use of bacteriophages in the context of antimicrobial resistance.
Company announced conclusion of an End-of-Phase 2 written response from the U.S. FDA and plans to advance an intravenously administered S. aureus bacteriophage product candidate into a Phase 3 clinical study.
Company hosted or published coverage of a multi-day public workshop addressing scientific and regulatory issues for bacteriophage therapy.
Company-hosted content addressing antimicrobial resistance, stewardship and the Priority Antimicrobial Value and Entry (PAVE) context.
Company-published article discussing renewed interest in bacteriophage therapy as an approach to antibiotic-resistant infections.
Company blog post discussing historical and modern use of bacteriophages in the context of antimicrobial resistance.
Company announced conclusion of an End-of-Phase 2 written response from the U.S. FDA and plans to advance an intravenously administered S. aureus bacteriophage product candidate into a Phase 3 clinical study.
Company hosted or published coverage of a multi-day public workshop addressing scientific and regulatory issues for bacteriophage therapy.
Company-hosted content addressing antimicrobial resistance, stewardship and the Priority Antimicrobial Value and Entry (PAVE) context.